两种不同方案治疗晚期非小细胞肺癌的临床探讨  

Clinical Trial of Two Chemotherapy Protocols for Advanced Non－Small Cell Lung Cancer

作　　者：汪安兰[1] 吴尉[1] 朱跃红[1] 袁志军[1] 肖立新[1] 林劲冠[1] 韩豫生 

机构地区：[1]湖南省肿瘤医院内科,长沙市410006

出　　处：《中国肿瘤临床》2001年第1期39-41,共3页Chinese Journal of Clinical Oncology

摘　　要：目的：观察去甲长春碱（NVB）联合异环磷酰胺（IFO）、顺铂（DDP）组成的INP方案及IFO与DDP和阿霉素（ADM）组成的IAP方案，治疗非小细胞肺癌（NSCLC）的疗效和安全性。方法：52例晚期NSCLC随机分为INP、IAP两组。结果：INP组有效率50．0％IAP组有效率38．4％，两组无显著性差异（P＞0．05）。INP组腺癌有效率64．3％，鳞癌有效率为33．3％IAP组腺癌有效率50．0％，鳞癌有效率28．6％，两组腺、鳞癌之间差异无显著性。两组剂量限制毒性为骨髓抑制，白细胞下降占100％，Ⅲ～Ⅳ度下降INP组为76．9％，IAP组53．8％。消化道反应可以耐受。结论：INP和IAP方案是治疗晚期非小细胞肺癌疗效高、可耐受的理想方案。以诺维本为主的联合方案可推荐作为复治的非小细胞肺癌第二线解救方案。Objective To evaluate the curative effects and safety of INP NVB＋IFO＋DDP regimen and IAP IFO＋ADM＋DDP regimen for non－small cell lung cancer NSCLC． Methods Fifty－two cases of advanced NSCLC were randomly divided into INP regimen group and IAP regimen group． Results The results showed that the response rates of INP group and IAP group were 50％ and 38．4％ respectively． There was no statistical significant difference between them P＞0．05． The response rates of adenocarcinoma and squamous cell carcinoma were 64．3％ and 33．3％ in INP group P＞0．05 50．0％ and 28．6％ in IAP group P＞0．05． The dose limiting toxicity was neutropenia which was seen in all treated cases 76．9％ and 53．8％ in grade Ⅲ and grade Ⅳ respectively and gastric irritation was tolerable． Conclusion All of these two regimens are effective and tolerable in the treatment of advanced NSCLC． It is recommended that NVB can be used as second－line regimen for retreatment of NSCLC．

关 键 词：非小细胞肺癌 去甲长春碱 异环磷酰胺 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R979[医药卫生—临床医学] 1